Literature DB >> 23110811

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.

A Gronchi1, P Verderio, A De Paoli, A Ferraro, O Tendero, J Majò, J Martin, A Comandone, G Grignani, S Pizzamiglio, V Quagliuolo, P Picci, S Frustaci, A P Dei Tos, E Palassini, S Stacchiotti, S Ferrari, M Fiore, P G Casali.   

Abstract

BACKGROUND: To explore correlation between the quality of surgery and outcome in high-risk soft tissue sarcoma (STS) patients treated within a phase III randomized trial. PATIENTS AND METHODS: In the trial, all patients received three cycles of preoperative chemotherapy (CT) with epirubicin 120 mg/m(2) and ifosfamide 9 g/m(2) and were randomly assigned to receive two further postoperative cycles. Radiotherapy (RT) could be delivered in the preoperative or postoperative setting. The association between surgical margins and overall survival (OS) was studied in a univariate and multivariate fashion.
RESULTS: Two hundred and fifty-two patients completed the whole treatment and were operated conservatively. At a median follow-up of 60 months (IQR, 45-74 months), the 5-year OS was 0.73, even in patients with positive and negative margins. The 5-year cumulative incidence (CI) of local recurrence (LR) in patients with positive and negative microscopic margins was 0.17 (standard error, SE, 0.08) and 0.03 (SE, 0.01), respectively. In the subgroup of patients receiving combined preoperative CT-RT and with positive surgical margins, the CI of LR was 0.
CONCLUSIONS: In this setting of high-risk STS treated by preoperative CT or CT-RT, the negative impact of positive margins on the outcome was limited. When close margins can be anticipated preoperative CT-RT may be a reasonable option to maximize the chance of cure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23110811     DOI: 10.1093/annonc/mds501

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival.

Authors:  Julie Willeumier; Marta Fiocco; Remi Nout; Sander Dijkstra; William Aston; Rob Pollock; Henk Hartgrink; Judith Bovée; Michiel van de Sande
Journal:  Int Orthop       Date:  2015-03-07       Impact factor: 3.075

2.  Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report.

Authors:  Sabino Strippoli; Michele Traversa; Antonio Cramarossa; Ondina Popescu; Vito Lorusso; Michele Guida
Journal:  Oncol Lett       Date:  2015-04-14       Impact factor: 2.967

Review 3.  Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications.

Authors:  Sandro Pasquali; Alessandro Gronchi
Journal:  Ther Adv Med Oncol       Date:  2017-04-16       Impact factor: 8.168

4.  Evaluation of two modalities of perioperative treatment in the management of extremity and truncal soft tissue sarcomas: neoadjuvant concurrent chemoradiotherapy and sequential treatment.

Authors:  J Attal; B Cabarrou; T Valentin; J P Nesseler; E Stoeckle; A Ducassou; T Filleron; S Le Guellec; B Boulet; G Vogin; G Ferron; E Cohen-Jonathan Moyal; M Delannes; C Chevreau
Journal:  Strahlenther Onkol       Date:  2021-10-21       Impact factor: 3.621

5.  The Width of the Surgical Margin Does Not Influence Outcomes in Extremity and Truncal Soft Tissue Sarcoma Treated With Radiotherapy.

Authors:  Rima Ahmad; Alex Jacobson; Francis Hornicek; Alex B Haynes; Edwin Choy; Gregory Cote; G Petur Nielsen; Yen-Lin Chen; Thomas F DeLaney; John T Mullen
Journal:  Oncologist       Date:  2016-07-20

6.  Use of negative pressure wound therapy as an adjunct to the treatment of extremity soft-tissue sarcoma with ulceration or impending ulceration.

Authors:  Y U Chen; Song-Feng Xu; Ming Xu; Xiu-Chun Yu
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

7.  Adjuvant therapy for high-risk soft tissue sarcoma in the adult.

Authors:  Alessandro Gronchi; Paolo G Casali
Journal:  Curr Treat Options Oncol       Date:  2013-09

8.  Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions.

Authors:  Benedetta Chiusole; Axel Le Cesne; Marco Rastrelli; Marco Maruzzo; Martina Lorenzi; Rocco Cappellesso; Paolo Del Fiore; Silvia Imbevaro; Marta Sbaraglia; Philippe Terrier; Pietro Ruggieri; Angelo Paolo Dei Tos; Carlo Riccardo Rossi; Vittorina Zagonel; Antonella Brunello
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

9.  Treatment of resectable intrathoracic sarcomas: a single institution experience over twenty years.

Authors:  David Rainey; Jacob Berriochoa; Anna Korpak; Jing Zeng; Elizabeth T Loggers; Robin L Jones; Shilpen Patel
Journal:  J Radiat Oncol       Date:  2015-12-16

Review 10.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.